Evaluation of the marker of hypercoagulability prothrombin fragment F 1+2 in patients with mechanical or biological heart valve prostheses

AUTOR(ES)

Ferreira, Claudia Natália, Vieira, Lauro Mello, Dusse, Luci Maria Sant'Ana, Amaral, Carlos Faria Santos, Esteves, William Antônio de Magalhães, Fenelon, Lúcia Maria Amorim, Carvalho, Maria das Graças

FONTE

Arquivos Brasileiros de Cardiologia

DATA DE PUBLICAÇÃO

2002-11

RESUMO

OBJECTIVE: To investigate whether patients with heart valve prostheses and similar International Normalized Ratios (INR) have the same level of protection against thromboembolic events, that is, whether the anticoagulation intensity is related to the intensity of hypercoagulability supression. METHODS: INR and plasma levels of prothrombin fragment 1+2 (F1+2) were assessed in blood samples of 27 patients (7 with mechanical heart valves and 20 with biological heart valves) and 27 blood samples from healthy donors that were not taking any medication. RESULTS: Increased levels of F1+2 were observed in blood samples of 5 patients with heart valve prostheses taking warfarin. These findings reinforce the idea that even though patients may have INRs, within the therapeutic spectrum, they are not free from new thromboembolic events. CONCLUSION: Determination of the hypercoagulability marker F1+2 might result in greater efficacy and safety for the use of oral anticoagulants, resulting in improved quality of life for patients.

Documentos Relacionados

• Comparison of Biological and Mechanical Prostheses for Heart Valve Surgery: A Systematic Review of Randomized Controlled Trials
• Annular injuries following the insertion of heart valve prostheses 1
• Doppler echocardiography in the study of patients with mitral disc valve prostheses.
• Generation of the combined prothrombin activation peptide (F1-2) during the clotting of blood and plasma.
• Doppler sonographic evaluation of mechanical and bioprosthetic mitral valve prostheses during exercise with a rate corrected pressure half time.